P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer

Hira Lal Goel, Bryan Pursell, Leonard D. Shultz, Dale L. Greiner, Rolf A. Brekken, Craig W. Vander Kooi, Arthur M. Mercurio

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Autocrine VEGF signaling is critical for sustaining prostate and other cancer stem cells (CSCs), and it is a potential therapeutic target, but we observed that CSCs isolated from prostate tumors are resistant to anti-VEGF (bevacizumab) and anti-VEGFR (sunitinib) therapy. Intriguingly, resistance is mediated by VEGF/neuropilin signaling, which is not inhibited by bevacizumab and sunitinib, and it involves the induction of P-Rex1, a Rac GEF, and consequent Rac1-mediated ERK activation. This induction of P-Rex1 is dependent on Myc. CSCs isolated from the PTENpc-/- transgenic model of prostate cancer exhibit Rac1-dependent resistance to bevacizumab. Rac1 inhibition or P-Rex1 downregulation increases the sensitivity of prostate tumors to bevacizumab. These data reveal that prostate tumors harbor cells with stem cell properties that are resistant to inhibitors of VEGF/VEGFR signaling. Combining the use of available VEGF/VEGFR-targeted therapies with P-Rex1 or Rac1 inhibition should improve the efficacy of these therapies significantly.

Original languageEnglish (US)
Pages (from-to)2193-2208
Number of pages16
JournalCell Reports
Volume14
Issue number9
DOIs
StatePublished - Mar 8 2016

Fingerprint

Vascular Endothelial Growth Factor A
Prostatic Neoplasms
Stem cells
Neoplastic Stem Cells
Tumors
Prostate
Neuropilins
Autocrine Communication
Therapeutics
Neoplasms
Ports and harbors
Stem Cells
Down-Regulation
Chemical activation
Bevacizumab
sunitinib

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Goel, H. L., Pursell, B., Shultz, L. D., Greiner, D. L., Brekken, R. A., Vander Kooi, C. W., & Mercurio, A. M. (2016). P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. Cell Reports, 14(9), 2193-2208. https://doi.org/10.1016/j.celrep.2016.02.016

P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. / Goel, Hira Lal; Pursell, Bryan; Shultz, Leonard D.; Greiner, Dale L.; Brekken, Rolf A.; Vander Kooi, Craig W.; Mercurio, Arthur M.

In: Cell Reports, Vol. 14, No. 9, 08.03.2016, p. 2193-2208.

Research output: Contribution to journalArticle

Goel, HL, Pursell, B, Shultz, LD, Greiner, DL, Brekken, RA, Vander Kooi, CW & Mercurio, AM 2016, 'P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer', Cell Reports, vol. 14, no. 9, pp. 2193-2208. https://doi.org/10.1016/j.celrep.2016.02.016
Goel HL, Pursell B, Shultz LD, Greiner DL, Brekken RA, Vander Kooi CW et al. P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. Cell Reports. 2016 Mar 8;14(9):2193-2208. https://doi.org/10.1016/j.celrep.2016.02.016
Goel, Hira Lal ; Pursell, Bryan ; Shultz, Leonard D. ; Greiner, Dale L. ; Brekken, Rolf A. ; Vander Kooi, Craig W. ; Mercurio, Arthur M. / P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. In: Cell Reports. 2016 ; Vol. 14, No. 9. pp. 2193-2208.
@article{f4435f75da6c4213b38fc34526cc00db,
title = "P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer",
abstract = "Autocrine VEGF signaling is critical for sustaining prostate and other cancer stem cells (CSCs), and it is a potential therapeutic target, but we observed that CSCs isolated from prostate tumors are resistant to anti-VEGF (bevacizumab) and anti-VEGFR (sunitinib) therapy. Intriguingly, resistance is mediated by VEGF/neuropilin signaling, which is not inhibited by bevacizumab and sunitinib, and it involves the induction of P-Rex1, a Rac GEF, and consequent Rac1-mediated ERK activation. This induction of P-Rex1 is dependent on Myc. CSCs isolated from the PTENpc-/- transgenic model of prostate cancer exhibit Rac1-dependent resistance to bevacizumab. Rac1 inhibition or P-Rex1 downregulation increases the sensitivity of prostate tumors to bevacizumab. These data reveal that prostate tumors harbor cells with stem cell properties that are resistant to inhibitors of VEGF/VEGFR signaling. Combining the use of available VEGF/VEGFR-targeted therapies with P-Rex1 or Rac1 inhibition should improve the efficacy of these therapies significantly.",
author = "Goel, {Hira Lal} and Bryan Pursell and Shultz, {Leonard D.} and Greiner, {Dale L.} and Brekken, {Rolf A.} and {Vander Kooi}, {Craig W.} and Mercurio, {Arthur M.}",
year = "2016",
month = "3",
day = "8",
doi = "10.1016/j.celrep.2016.02.016",
language = "English (US)",
volume = "14",
pages = "2193--2208",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "9",

}

TY - JOUR

T1 - P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer

AU - Goel, Hira Lal

AU - Pursell, Bryan

AU - Shultz, Leonard D.

AU - Greiner, Dale L.

AU - Brekken, Rolf A.

AU - Vander Kooi, Craig W.

AU - Mercurio, Arthur M.

PY - 2016/3/8

Y1 - 2016/3/8

N2 - Autocrine VEGF signaling is critical for sustaining prostate and other cancer stem cells (CSCs), and it is a potential therapeutic target, but we observed that CSCs isolated from prostate tumors are resistant to anti-VEGF (bevacizumab) and anti-VEGFR (sunitinib) therapy. Intriguingly, resistance is mediated by VEGF/neuropilin signaling, which is not inhibited by bevacizumab and sunitinib, and it involves the induction of P-Rex1, a Rac GEF, and consequent Rac1-mediated ERK activation. This induction of P-Rex1 is dependent on Myc. CSCs isolated from the PTENpc-/- transgenic model of prostate cancer exhibit Rac1-dependent resistance to bevacizumab. Rac1 inhibition or P-Rex1 downregulation increases the sensitivity of prostate tumors to bevacizumab. These data reveal that prostate tumors harbor cells with stem cell properties that are resistant to inhibitors of VEGF/VEGFR signaling. Combining the use of available VEGF/VEGFR-targeted therapies with P-Rex1 or Rac1 inhibition should improve the efficacy of these therapies significantly.

AB - Autocrine VEGF signaling is critical for sustaining prostate and other cancer stem cells (CSCs), and it is a potential therapeutic target, but we observed that CSCs isolated from prostate tumors are resistant to anti-VEGF (bevacizumab) and anti-VEGFR (sunitinib) therapy. Intriguingly, resistance is mediated by VEGF/neuropilin signaling, which is not inhibited by bevacizumab and sunitinib, and it involves the induction of P-Rex1, a Rac GEF, and consequent Rac1-mediated ERK activation. This induction of P-Rex1 is dependent on Myc. CSCs isolated from the PTENpc-/- transgenic model of prostate cancer exhibit Rac1-dependent resistance to bevacizumab. Rac1 inhibition or P-Rex1 downregulation increases the sensitivity of prostate tumors to bevacizumab. These data reveal that prostate tumors harbor cells with stem cell properties that are resistant to inhibitors of VEGF/VEGFR signaling. Combining the use of available VEGF/VEGFR-targeted therapies with P-Rex1 or Rac1 inhibition should improve the efficacy of these therapies significantly.

UR - http://www.scopus.com/inward/record.url?scp=84960407547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960407547&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2016.02.016

DO - 10.1016/j.celrep.2016.02.016

M3 - Article

C2 - 26923603

AN - SCOPUS:84960407547

VL - 14

SP - 2193

EP - 2208

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 9

ER -